Dr. Reddy's Laboratories Limited (RDY)
USD 14.0
(1.23%)
USD 14.0
(1.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 82.57 Billion INR | 18.8% |
| 2023 | 74.43 Billion INR | 106.65% |
| 2022 | 47.74 Billion INR | 7.74% |
| 2021 | 45.7 Billion INR | -1.35% |
| 2020 | 41.78 Billion INR | 109.81% |
| 2019 | 31.86 Billion INR | 98.09% |
| 2018 | 23.73 Billion INR | -11.71% |
| 2017 | 24.54 Billion INR | -54.43% |
| 2016 | 40.17 Billion INR | 12.68% |
| 2015 | 35.15 Billion INR | 0.98% |
| 2014 | 33.13 Billion INR | 15.75% |
| 2013 | 22.48 Billion INR | 10.61% |
| 2012 | 20.33 Billion INR | 61.04% |
| 2011 | 16.82 Billion INR | -16.88% |
| 2010 | 6.58 Billion INR | -2.07% |
| 2009 | 1.48 Billion INR | 84.75% |
| 2008 | 7.3 Billion INR | -45.65% |
| 2007 | 14.26 Billion INR | 470.48% |
| 2006 | 2.7 Billion INR | 227.66% |
| 2005 | 1.02 Billion INR | -70.86% |
| 2004 | 2.83 Billion INR | -30.45% |
| 2003 | 4.35 Billion INR | -27.7% |
| 2002 | 6 Billion INR | 143.47% |
| 2001 | 2.37 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | 18.49 Billion INR | -14.43% |
| 2024 Q3 | 21.28 Billion INR | 6.55% |
| 2024 Q1 | 17.65 Billion INR | 26.35% |
| 2024 Q2 | 22.03 Billion INR | -4.4% |
| 2024 FY | - INR | -24.09% |
| 2023 Q3 | 19.24 Billion INR | -2.41% |
| 2023 Q4 | 25 Billion INR | 29.93% |
| 2023 FY | - INR | 106.65% |
| 2023 Q2 | 19.72 Billion INR | 26.82% |
| 2023 Q1 | 15.55 Billion INR | 50.79% |
| 2022 Q3 | 12.68 Billion INR | -12.27% |
| 2022 Q4 | 10.31 Billion INR | -18.66% |
| 2022 Q2 | 14.45 Billion INR | 46.61% |
| 2022 Q1 | 9.85 Billion INR | 17.6% |
| 2022 FY | - INR | 7.74% |
| 2021 Q1 | 11.6 Billion INR | 75.42% |
| 2021 FY | - INR | -1.35% |
| 2021 Q2 | 9.87 Billion INR | -14.93% |
| 2021 Q3 | 9 Billion INR | -8.81% |
| 2021 Q4 | 8.38 Billion INR | -6.89% |
| 2020 Q1 | 11.41 Billion INR | 87.17% |
| 2020 FY | - INR | 109.81% |
| 2020 Q4 | 6.61 Billion INR | -18.1% |
| 2020 Q3 | 8.07 Billion INR | -26.8% |
| 2020 Q2 | 11.03 Billion INR | -3.28% |
| 2019 Q2 | 7.9 Billion INR | 0.11% |
| 2019 Q1 | 7.89 Billion INR | 198.41% |
| 2019 FY | - INR | 98.09% |
| 2019 Q3 | 6.32 Billion INR | -20.08% |
| 2019 Q4 | 6.09 Billion INR | -3.54% |
| 2018 Q2 | 6.89 Billion INR | 97.28% |
| 2018 FY | - INR | -11.71% |
| 2018 Q4 | 2.64 Billion INR | -47.16% |
| 2018 Q3 | 5 Billion INR | -27.4% |
| 2018 Q1 | 3.49 Billion INR | 11.55% |
| 2017 FY | - INR | -54.43% |
| 2017 Q3 | 8.86 Billion INR | 38.56% |
| 2017 Q2 | 6.39 Billion INR | 51.64% |
| 2017 Q1 | 4.21 Billion INR | -16.84% |
| 2017 Q4 | 3.13 Billion INR | -64.62% |
| 2016 Q2 | 12.06 Billion INR | 15.9% |
| 2016 Q3 | 10.54 Billion INR | -12.57% |
| 2016 FY | - INR | 12.68% |
| 2016 Q1 | 10.4 Billion INR | 70.03% |
| 2016 Q4 | 5.07 Billion INR | -51.9% |
| 2015 FY | - INR | 0.98% |
| 2015 Q2 | 8.73 Billion INR | 0.78% |
| 2015 Q1 | 8.66 Billion INR | 47.95% |
| 2015 Q4 | 6.12 Billion INR | -36.92% |
| 2015 Q3 | 9.7 Billion INR | 11.11% |
| 2014 FY | - INR | 15.75% |
| 2014 Q4 | 5.85 Billion INR | -42.51% |
| 2014 Q3 | 10.18 Billion INR | 8.43% |
| 2014 Q2 | 9.39 Billion INR | 54.13% |
| 2014 Q1 | 6.09 Billion INR | -17.96% |
| 2013 Q4 | 7.42 Billion INR | 16.92% |
| 2013 Q1 | 5.47 Billion INR | -12.43% |
| 2013 Q2 | 6.59 Billion INR | 20.39% |
| 2013 FY | - INR | 10.61% |
| 2013 Q3 | 6.35 Billion INR | -3.58% |
| 2012 Q1 | 4.21 Billion INR | -14.14% |
| 2012 Q3 | 7.54 Billion INR | 44.41% |
| 2012 FY | - INR | 61.04% |
| 2012 Q4 | 6.25 Billion INR | -17.17% |
| 2012 Q2 | 5.22 Billion INR | 24.04% |
| 2011 Q2 | 4.33 Billion INR | 58.74% |
| 2011 FY | - INR | -16.88% |
| 2011 Q4 | 4.9 Billion INR | 22.49% |
| 2011 Q3 | 4 Billion INR | -7.53% |
| 2011 Q1 | 2.72 Billion INR | -13.56% |
| 2010 Q1 | 4.49 Billion INR | -21.08% |
| 2010 Q2 | 3.84 Billion INR | -14.53% |
| 2010 Q3 | 3.74 Billion INR | -2.5% |
| 2010 Q4 | 3.15 Billion INR | -15.68% |
| 2010 FY | - INR | -2.07% |
| 2009 Q3 | 4.76 Billion INR | 66.79% |
| 2009 FY | - INR | 84.75% |
| 2009 Q4 | 5.69 Billion INR | 19.46% |
| 2009 Q2 | 2.85 Billion INR | 42.93% |
| 2009 Q1 | 1.99 Billion INR | -11.49% |
| 2008 Q3 | 1.79 Billion INR | -18.54% |
| 2008 FY | - INR | -45.65% |
| 2008 Q1 | 2.58 Billion INR | -45.01% |
| 2008 Q2 | 2.2 Billion INR | -14.89% |
| 2008 Q4 | 2.25 Billion INR | 25.92% |
| 2007 Q1 | 2.75 Billion INR | 295.44% |
| 2007 Q3 | 3.08 Billion INR | -36.85% |
| 2007 Q2 | 4.87 Billion INR | 77.19% |
| 2007 FY | - INR | 470.48% |
| 2007 Q4 | 4.7 Billion INR | 52.69% |
| 2006 Q2 | 892.13 Million INR | 52.36% |
| 2006 Q1 | 585.56 Million INR | 218.69% |
| 2006 FY | - INR | 227.66% |
| 2006 Q4 | 696.3 Million INR | 30.04% |
| 2006 Q3 | 535.46 Million INR | -39.98% |
| 2005 Q1 | 550.39 Million INR | 62.91% |
| 2005 Q4 | -493.36 Million INR | -560.21% |
| 2005 Q3 | 107.2 Million INR | -84.95% |
| 2005 FY | - INR | -70.86% |
| 2005 Q2 | 712.21 Million INR | 29.4% |
| 2004 Q1 | 895.3 Million INR | -14.05% |
| 2004 FY | - INR | -30.45% |
| 2004 Q3 | 634.87 Million INR | -34.65% |
| 2004 Q4 | 337.84 Million INR | -46.79% |
| 2004 Q2 | 971.47 Million INR | 8.51% |
| 2003 Q2 | 1.16 Billion INR | -33.92% |
| 2003 FY | - INR | -27.7% |
| 2003 Q1 | 1.49 Billion INR | 43.73% |
| 2003 Q3 | 886.23 Million INR | -22.09% |
| 2003 Q4 | 810.12 Million INR | 44.89% |
| 2002 Q1 | 746.32 Million INR | 0.0% |
| 2002 Q2 | 2.45 Billion INR | 218.04% |
| 2002 FY | - INR | 143.47% |
| 2002 Q4 | 1.1 Billion INR | -39.48% |
| 2002 Q3 | 1.7 Billion INR | -31.09% |
| 2001 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 500.78 Million USD | -16389.011% |
| Bausch Health Companies Inc. | 2.88 Billion USD | -2762.184% |
| Catalent, Inc. | -284 Million USD | 29175.352% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 16441.579% |
| Elanco Animal Health Incorporated | -224 Million USD | 36963.393% |
| Perrigo Company plc | 646.2 Million USD | -12678.397% |
| Teva Pharmaceutical Industries Limited | 4.33 Billion USD | -1805.7% |
| Zoetis Inc. | 3.68 Billion USD | -2140.814% |